



US008518929B2

(12) **United States Patent**  
**Manku et al.**

(10) **Patent No.:** US 8,518,929 B2  
(45) **Date of Patent:** \*Aug. 27, 2013

(54) **METHODS OF TREATING HYPERTRIGLYCERIDEMIA**(71) Applicant: **Amarin Pharmaceuticals Ireland Limited**, Dublin (IE)(72) Inventors: **Mehar Manku**, England (GB); **Ian Osterloh**, Kent (GB); **Pierre Wicker**, Mystic, CT (US); **Rene Braeckman**, Richboro, PA (US); **Paresh Soni**, Mystic, CT (US)(73) Assignee: **Amarin Pharmaceuticals Ireland Limited**, Dublin (IE)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 13/776,242

(22) Filed: Feb. 25, 2013

(65) **Prior Publication Data**

US 2013/0171249 A1 Jul. 4, 2013

**Related U.S. Application Data**

(63) Continuation of application No. 13/711,329, filed on Dec. 11, 2012, now Pat. No. 8,431,560, which is a continuation of application No. 13/623,450, filed on Sep. 20, 2012, now Pat. No. 8,377,920, which is a continuation of application No. 13/349,153, filed on Jan. 12, 2012, now Pat. No. 8,293,728, which is a continuation of application No. 12/702,889, filed on Feb. 9, 2010, now Pat. No. 8,293,727.

(60) Provisional application No. 61/151,291, filed on Feb. 10, 2009, provisional application No. 61/173,755, filed on Apr. 29, 2009.

(51) **Int. Cl.**

|                   |           |
|-------------------|-----------|
| <i>A61K 9/48</i>  | (2006.01) |
| <i>A61K 31/33</i> | (2006.01) |
| <i>A61K 31/02</i> | (2006.01) |
| <i>A01N 43/00</i> | (2006.01) |
| <i>A01N 37/06</i> | (2006.01) |

(52) **U.S. Cl.**

USPC ..... 514/183; 514/549; 424/451

(58) **Field of Classification Search**

USPC ..... 514/183, 549; 424/451

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**

|             |        |                    |
|-------------|--------|--------------------|
| 4,377,526 A | 3/1983 | Fujita et al.      |
| 4,526,902 A | 7/1985 | Rubin              |
| 4,920,098 A | 4/1990 | Cotter et al.      |
| 4,935,243 A | 6/1990 | Borkan et al.      |
| 5,013,443 A | 5/1991 | Higashidate et al. |
| 5,116,871 A | 5/1992 | Horrobin et al.    |
| 5,178,873 A | 1/1993 | Horrobin et al.    |

|                |         |                              |
|----------------|---------|------------------------------|
| 5,198,468 A    | 3/1993  | Horrobin                     |
| 5,215,630 A    | 6/1993  | Hata et al.                  |
| 5,252,333 A    | 10/1993 | Horrobin                     |
| 5,457,130 A    | 10/1995 | Tisdale et al.               |
| 5,502,077 A    | 3/1996  | Breivik et al.               |
| 5,567,730 A    | 10/1996 | Miyashita et al.             |
| 5,589,508 A    | 12/1996 | Schlotzer et al.             |
| 5,603,959 A    | 2/1997  | Horrobin et al.              |
| 5,618,558 A    | 4/1997  | Horrobin et al.              |
| 5,656,667 A    | 8/1997  | Breivik et al.               |
| 5,698,594 A    | 12/1997 | Breivik et al.               |
| 5,760,081 A    | 6/1998  | Leaf et al.                  |
| 5,776,978 A    | 7/1998  | Bruzzeze                     |
| 5,837,731 A    | 11/1998 | Vaddadi                      |
| 5,840,944 A    | 11/1998 | Furihata et al.              |
| 5,888,541 A    | 3/1999  | Horrobin et al.              |
| 6,069,168 A    | 5/2000  | Horrobin et al.              |
| 6,193,999 B1   | 2/2001  | Gennadios                    |
| 6,326,031 B1   | 12/2001 | Hsia et al.                  |
| 6,331,568 B1   | 12/2001 | Horrobin                     |
| 6,368,621 B1   | 4/2002  | Engel et al.                 |
| 6,384,077 B1   | 5/2002  | Peet                         |
| 6,479,544 B1   | 11/2002 | Horrobin                     |
| 6,531,150 B1   | 3/2003  | Sunohara et al.              |
| 6,555,700 B1   | 4/2003  | Horrobin et al.              |
| 6,689,812 B2   | 2/2004  | Peet                         |
| 7,119,118 B2   | 10/2006 | Peet                         |
| 7,498,359 B2 * | 3/2009  | Yokoyama et al. .... 514/529 |
| 8,188,146 B2   | 5/2012  | Peet et al.                  |
| 8,293,727 B2   | 10/2012 | Manku et al.                 |
| 8,293,728 B2   | 10/2012 | Manku et al.                 |
| 8,298,554 B2   | 10/2012 | Manku                        |
| 8,314,086 B2   | 11/2012 | Manku et al.                 |

(Continued)

**FOREIGN PATENT DOCUMENTS**

|    |         |         |
|----|---------|---------|
| CA | 2628305 | 5/2007  |
| CA | 2653787 | 12/2007 |

(Continued)

**OTHER PUBLICATIONS**

Katayama et. al. (Prog. Med. (2001) 21:457-467, translated from Japanese).\*

Mori et. al. (Mori I, Am. J. Clin. Nutr. (2000) 71:1085-1094).\*

Okumura et. al. (The American Journal of medical Sciences (2002) 324:247-253).\*

Hayashi et. al. (Current Therapeutic research (1995) 56:24-31).\*

Grimsgaard et. al. (Am. J. Clin. Nutr. (1997) 66:649-659).\*

Mori et. al. (Curr. Opinion Clin. Nutr. Metab. Care (2006) 9:95-104).\*

Aarsland, et al., "On the Effect of Peroxisomal β-Oxidation and Carnitine Palmitoyltransferase Activity by Eicosapentaenoic Acid in Liver and Heart of Rats." Lipids, 25:546-548, (1990).

Aas, V., et al., "Eicosapentaenoic acid (20:5 n-3) increases fatty acid and glucose uptake in cultured human skeletal muscle cells." Journal of Lipid Research, 47:366-374 (2006).

(Continued)

Primary Examiner — Marcos Sznajdman

(74) Attorney, Agent, or Firm — Perkins Coie LLP

(57) **ABSTRACT**

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.